ZEVALIN is a form of cancer therapy called radioimmunotherapy, and is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL, including patients with Rituximab-refractory NHL. Zevalin was approved by the Food and Drug Administration (FDA) in February of 2002 as the first radioimmunotherapy agent for the treatment of NHL.
Indications:
ZEVALIN® (Ibritumomab Tiuxetan), as part of the ZEVALIN therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with Rituximab-refractory follicular NHL.
Determination of the effectiveness of the ZEVALIN therapeutic regimen in a relapsed or refractory patient population is based on overall response rates. The effects of the ZEVALIN therapeutic regimen on survival are not known.
Patient selection: Appropriate patients
Less than 25% lymphoma involvement in bone marrow and/or no impaired bone marrow reserve, for example, prior myeloablative therapies.
More than 15% bone marrow cellularity and no marked reduction in bone marrow precursors.
A platelet count greater than 100,000 cells/mm3.
An absolute neutrophil count (ANC) greater than 1,500 cells/mm3.
No history of failed stem cell collection.
No known Type I hypersensitivity or anaphylactic reations to the following: murine proteins, Rituximab, yttrium chloride and indium chloride.
Neither patient age (18 plus) nor the presence or absence of bulky disease affects patient eligibility to receive the ZEVALIN therapeutic regimen. ZEVALIN Treatment Team:
Patient Coordinator: Beverly Cratch
Radiation Oncology: Suzanne Russo M.D.
Department of Radiation Oncology
The Brody School of Medicine at East Carolina University
600 Moye Blvd.
Greenville, NC 27834
Phone (252) 744-2900 / Fax (252) 744-2812
